Genome-wide association studies (GWASs) identified over 500 single nucleotide polymorphisms (SNPs) influencing cancer risk. It is logical to expect the cancer-associated genes to cluster in pathways directly involved in carcinogenesis, e.g. cell cycle. Nevertheless, analyses of the GWAS-detected cancer risk genes usually show no or weak enrichment by known cancer genes. We hypothesized that GWAS-detected cancer risk-associated genes function as upstream regulators of the genes directly involved in carcinogenesis. We have analyzed four common cancers: breast, colon, lung, and prostate. To identify downstream targets of GWAS-detected cancer risk genes we used MedScan, which is a text mining tool offered by PathwayStudio. We also used data on protein/protein interactions reported by BioGRID database. Among all identified targets we have selected common downstream targets. A gene was considered a common downstream target if it was a downstream target for at least three GWAS-detected genes for a given cancer type. Common downstream targets were identified separately for each cancer type. We found that common downstream targets for all four cancer types were enriched by cell cycle genes, more specifically, the genes involved in G1/S transition. Common downstream targets for bipolar disorder, Crohn's disease, and type 2 diabetes did not show G1/S transition enrichment. The results of this analysis suggest that many cancer risk genes function as upstream regulators of the genes directly involved in G1/S transition and exert their risk effects by reducing threshold for G1/S transition, elevating the background level of cell proliferation and cancer risk.
Introduction
Genome-wide association studies (GWASs) findings are reported in several publicly available databases (1, 2) . One of the most comprehensive, manually curated databases is the Catalog of Published GWASs (CP GWAS ) (3) (http://www.genome. gov/gwastudies/). At the moment of accession (March, 2016), the database comprised over 200 cancer GWASs identifying more than 800 risk-associated SNPs mapped to over 300 genes.
According to CPGWAS, the majority (85%) of the GWAS-detected SNPs are mapped to a single gene.
Aside from uncovering the genetic architecture of common human diseases and conditions, GWAS may help to identify risk-associated biological functions. In this study we are focusing on functions/pathways associated with cancer risk. It is well established that carcinogenesis is associated with disruption of a number of basic biological functions including cell proliferation, apoptosis, angiogenesis and others (4, 5) . It is logical to expect that cancer risk-associated genes will be associated with those functions. However, functional annotation of GWAS-detected cancer risk-associated genes shows little or no enrichment by genes from key cancer pathways (6) (7) (8) (9) . This result is unexpected and intriguing.
We hypothesized that many GWAS-detected cancer riskassociated genes function as upstream regulators of the genes directly involved in cancer development. The hypothesis predicts that downstream targets of the GWAS-detected cancer genes will be enriched by cancer-associated genes. In this analysis, we focused on common downstream targets that were defined as genes with at least three upstream regulators that were GWAS-detected genes for a given cancer/disease (e.g. lung cancer). Figure 1 shows schematics of common downstream target definition.
Results
We tested the hypothesis that downstream signaling of GWASdetected cancer risk-associated genes converges to a small number of genes/functions directly relevant to cancer development. According to the CP GWAS database, there are 113 GWASdetected risk-associated genes for breast, 42 for colon, 62 for lung, and 115 for prostate cancer. We also analyzed three common non-cancer diseases (Crohn's disease, bipolar disorder, and Type 2 diabetes). These diseases were selected because they are most studied, with the highest number of GWASdetected risk-associated genes: 227 genes for the Crohn's disease, 186 genes for bipolar disorder, and 154 genes for the Type 2 diabetes (Table 1) .
Supplementary Material, Table S1 shows MedScan data on direct gene/gene regulations and BioGRID data on protein/protein interactions for known GWAS detected genes. The numbers of potential downstream targets of GWAS-detected risk-associated genes were: 3,622 for breast cancer, 3,058 for colon cancer, 1,725 for lung cancer, and 3,015 for prostate cancer. For noncancerous diseases, there were 2,546 reported gene/gene regulations for bipolar disorder, 11,405 for Crohn's disease, and 5,402 for the Type II diabetes. Common downstream targets comprised about 7% of all targets of GWAS-detected genes. Supplementary Material, Table S2 provides a list of common downstream targets for the analyzed diseases. The majority of common downstream targets (95%) are disease-specific. Twelve genes: AKT1, APP, BCL2, CDK2, CDKN2A, EGFR, FN1, GSK3B, JUN, MAPK1, MAPK8, and RELA are common downstream targets for all analyzed diseases -cancers and non-cancers. The level of overlap is significantly higher than one can expect by chance (v 2 ¼ 9.4, df ¼ 1, P ¼ 0.002). A higher than expected level of overlap can be due to the fact that we are using a set of diseases (in particular different types of cancers) that share the same (or strongly overlapping) molecular functions. Such overlap may also exist between cancer and other diseases (10, 11) .
We assessed functional enrichment of two groups of genes: (1) Disease risk-associated genes reported by the CP GWAS and (2) common downstream targets. Table 2 shows top three pathways identified for each set of genes. Analysis of GWASdetected cancer risk-associated genes showed modest (often borderline) functional enrichment (left part of Table 2 ). On the other hand, analyses of common downstream targets showed a much stronger functional enrichment (right panel of Table 2 ). In all four cancer types, common downstream targets are enriched by the genes directly involved in the regulation of cell cycle, more specifically transition from G1 to S phase. Figure 2 shows BioCarta G1/S transition pathway, with colormarked common downstream targets for each cancer type. The figure shows that virtually all genes in the pathway are common downstream targets for GWAS-detected cancer riskassociated genes.
GWAS-detected cancer risk-associated genes themselves do not show enrichment by the genes directly involved in G1/S transition. Only one (FGF10) (12) out of 127 genes that are involved in G1/S transition according to Gene Ontology (GO) database was among GWAS-detected cancer risk-associated genes.
We also conducted a pooled analysis of all cancer riskassociated genes. We combined genes for breast, colon, lung and prostate cancer (total 309 genes) and detected a borderline enrichment for cell cycle genes (P ¼ 4.9Â10 À 2 ).
We also performed an enrichment analysis for all targets (not just common downstream targets). The results of the analysis are shown in Supplementary Material, Table S3. In the analysis of all downstream targets of cancer risk-associated genes we detected the same (or related) pathways as in the common downstream target analyses. However, P-values tended to be less significant compared to the analysis of common downstream targets.
Enrichment analyses stratified by Common Downstream Targets (CDT) detection method (text mining versus protein/ protein interactions (PPI)) produced results very similar to the analysis based on CDTs identified by the combination of text mining and PPIs. All analyses showed significant enrichment for cell cycle after adjusting for multiple testing, except for PPIdefined CDTs for colorectal cancer, where it did not reach the level of statistical significance (Benjamini-Hochberg corrected P ¼0.08), possibly due to the fact that the identified number of CDTs was small (12) and the analysis was underpowered to detect enrichment.
Permutation analysis (random sampling of GWAS-detected risk-associated genes) failed to identify G1/S transition enrichment among CDTs for randomly selected genes (shown in Supplementary Material, Table S4 ). Three pathways remained significant (in at least one permutation run) after Benjamini correction for multiple testing: MAPKinase Signaling (P ¼ 0.007), Cytokines and Inflammatory Response (P ¼ 0.02), and EGF Signaling (P ¼ 0.04). The results of the analysis stratified by the level of statistical significance of GWAS-detected disease-associated SNPs were consistent with the results of the all-inclusive analysis. A functional enrichment analysis of CDTs of the genes with genomewide level of significance (GWLS) and CDTs of sub-significant (SS) genes both identified cell cycle as the top function. A functional enrichment analysis conducted after exclusion of SS genes reported in GWSL set for a given disease identified cell cycle in all cancers except lung cancer where it was borderline significant (5.6Â10
). We did not detect clustering of CDTs of GWSL and SS genes in cell cycle in three analyzed noncancerous diseases (Supplementary Material S1).
Discussion
In most cases enrichment analyses of GWAS-detected cancer risk-associated genes show little or no evidence of functional clustering (13) (14) (15) (16) . In this study, we also observed a very weak functional enrichment when risk-associated genes were analyzed directly. We hypothesized that the risk associated genes act as upstream regulators for the genes directly involved in cancer development. Many genes in the human genome are regulated by multiple genes with an average gene in the human genome having $40 upstream regulators (17) (18) (19) . Thus, it is plausible that genes directly involved in cancer development may have upstream regulators among GWAS-detected cancer risk-associated genes. Genes directly involved in cancer development may not be detected as risk associated by GWASs because they are extremely functionally loaded with many of them being housekeeping genes (20) . It is known that functionally important genes show lower rate of evolution and tend to be more monomorphic at the population level (21) (22) (23) . Dearth of functional polymorphisms in genes directly involved in cancer development makes them "invisible" for GWASs. Upstream regulators of those genes are likely to have a more subtle effect on their functions which, however, may be sufficient to elevate cancer risk.
We found that common downstream targets of GWASdetected cancer genes are enriched by genes involved in G1/S transition. The results of the enrichment analyses were similar for four studied cancer types. The results were also similar for CDTs identified by the combination or text mining and PPIs and for CDTs identified by stratified analyses: text mining or PPIs only. In the combined direct analysis of all GWAS-detected cancer risk-associated genes, the cell cycle pathway was borderline significant, suggesting that cell cycle gene enrichment exists among risk-associated genes but it is too weak to be detected by analyses of individual cancers. The enrichment analysis of all targets identified the same or related pathways as common downstream target analysis (Supplementary Material, Table S3 ).
However, the results tended to be less significant compared to the results generated by the analysis of common downstream targets. This may be a result of a higher proportion of false positives among all targets compared to common downstream targets.
Our analysis indicates that CDT enrichment by the genes involved in G1/S transition is likely to be cancer-specific. We found no or very weak enrichment of CDTs for the three most studied non-cancerous diseases by the genes involved in G1/S transition. Random sampling (permutation analysis) of GWASdetected risk-associated genes also found no enrichment of CDTs by G1/S transition genes.
The results of the analysis stratified by the level of statistical significance provide further support for the idea that downstream target genes for GWAS-detected cancer risk associated genes cluster in the cell cycle pathway. The results also suggest that sub-significant genes with P values lower than 10 À 5 but not reaching genome wide level of statistical significance are enriched by the genes whose CDTs are associated with regulation of cell cycle.
G1/S model of cancer risk
Based on the results of this analysis, we propose a G1/S transition model of cancer risk. According to the model, many cancer risk-associated genes elevate cancer risk by decreasing a threshold for G1/S transition. G1/S transition is a key decision point in mitotic cell cycle. It is a "point of no return", beyond which the cell is left with a choice to divide or to die (24, 25) . G1/S transition is a natural downstream target for the genes modulating cancer risk. We hypothesize that cancer riskassociated genes lower the threshold for entering G1/S transition and therefore elevate the background cell proliferation rate. It is known that elevated background cell proliferation is associated with elevated cancer risk (26) (27) (28) (29) . Tumor development can be further accelerated by accumulating of somatic mutations which allow mutated cells to survive and proliferate (30) (31) (32) .
To our knowledge, G1/S model is the first data-driven model for common biological mechanisms by which GWAS-detected SNPs increase cancer risk. The proposed G1/S transition model of cancer risk is supported by the results of several recent very large cancer GWASs. As stated above, functional polymorphisms in genes directly involved in cancer development are rare and the power to detect them can only be achieved by high sample sizes. By using a large number of subjects, SNPs in three genes directly involved in G1/S transition, namely in CDK10 for melanoma (43,44), EIF4E2 for lung cancer (45), and EGFR for glioma have been identified. EGFR is also CDT for breast, colon, lung and prostate cancer. One can expect that larger, ) better-powered GWASs will identify more G1/S transition genes associated with cancer risk.
Materials and Methods
GWAS-detected risk-associated genes were retrieved from the CP GWAS http://www.genome.gov/gwastudies/ (accessed March 2016). The database provides the information on mapped genes (gene(s) mapped to the strongest SNP) and reported genes (gene(s) reported by author of the study). Mapped and reported genes are the same in over 90% cases. We used mapped genes from CP GWAS . We used BioCarta pathways for functional classification implemented in Database for Annotation, Visualization and Integrated Discovery (DAVID) (33) . We used DAVID because it provides expanded back-end annotation (34) and advanced modular enrichment algorithm (35) . Functional enrichment analysis was performed separately for (i) GWAS-detected cancer risk associated genes (GWAS genes) and (ii) common downstream targets. We separately analyzed seven diseases (listed in alphabetical order): bipolar disorder, breast cancer, colon cancer, Crohn's disease, lung cancer, prostate cancer, and type II diabetes. Text mining and data on protein/protein interactions were used to identify downstream targets for the GWAS detected genes. We used MedScan for text mining. MedScan is part of the Pathway Studio suite (36) . MedScan "reads" abstracts to identify reports on direct gene/gene interactions. The software identifies sentences like "We found that the gene X (which is a GWASdetected cancer risk gene) regulates expression of the gene Y (which can be any gene from the human genome)". MedScan utilizes grammar rules to identify relationships between biological entities, in our case genes. MedScan identifies ten predefined types of relationships between entities. All relations have directionality. To minimize chances of false-positives we used interactions supported by at least two independent studies.
Protein/protein interaction data were retrieved from the BioGRID database (37) . The BioGRID comprises data on more than 70,000 protein/protein interactions detected by affinity capture mass spectrometry, two-hybrid system and other methods. We used only unique/heterogeneous interactions, i.e. those interactions that involve two different proteins as opposed to homodimerization which includes the same protein.
Among unique heterogeneous interactions we identified a subset where at least one of the interacting proteins was encoded by a GWAS-detected gene.
A gene was considered to be a potential downstream target for a given GWAS-detected gene when at least one of the following two conditions was met: (1) the gene was reported to be a downstream target for a GWAS-detected gene by at least two independent studies, or (2) there was a direct protein/protein interaction with a GWAS-detected gene. One cannot say if a GWAS-detected gene is an upstream regulator or a downstream target based on protein/protein interactions alone. However, more than 80% of interactions we have used came from text mining with the reported directionality of regulations.
All potential downstream targets identified by text mining and protein/protein interactions are listed in Supplementary Material, Table S1 . Our next step was to examine the variation in the overall number of the upstream regulators among the identified targets. The reason for this was that genes with a high total number of upstream regulators would have a higher probability to have a GWAS-detected gene among upstream regulators. Using the same MedScan text mining tool we determined the number of upstream regulators for each target, noting a substantial variation in this number among the targets. This variation likely reflects, among other things, the level of research interest to the gene and its product. For example, TP53 gene was found to have 1,389 known upstream regulators, while DPF1 had only one reported upstream regulator.
To determine if upstream regulators for a given gene are enriched by GWAS-detected genes, we needed to account for the total number of reported upstream regulators. For this purpose, we used a binominal distribution to assess the probability of the observed number of GWAS-detected genes among upstream regulators assuming there was no enrichment. For the binomial distribution, success was defined as a case when a GWAS-detected gene was an upstream regulator of a given gene i. The number of successes for the i th target gene was denoted as NS i , and the total number of upstream regulators for i th target gene (the number of trials) as N i . The probability P of success in one trial, that is, the probability that a randomly chosen gene will be a GWAS-detected risk-associated gene, was estimated as N GWAS =20161, where N GWAS is the number of GWAS-detected genes for a given disease and 20,162 is the number of validated genes in the human genome, according to RefSeq database (38) . The binomial probability to have NS i upstream regulators that are GWAS-detected genes (successes) among N i known upstream regulators for the i th target gene (trials) follows a binominal distribution:
We declared a gene as a downstream target of GWASdetected genes for a given disease when the inequality f NS i ; N i ; p ð Þ 0.05/N Targets held true, where N Targets is the number of the target genes examined -this number is used to correct for multiple testing following the Bonferroni adjustment. We used a similar approach to identify significant protein/protein interactions.
Our hypothesis was that the downstream effects of genes associated with cancer risk merge to a small number of target genes that are directly involved in cancer development. Therefore, after we identified the downstream targets as genes showing a significant enrichment with GWAS-detected riskassociated genes, we imposed a further condition on the target genes that there be no less than three GWAS-detected genes among the upstream regulators, and the resulting target genes were considered common downstream targets. In other words, the common downstream targets were defined as genes with a significant enrichment of their upstream regulators by the GWAS-detected genes, which moreover had at least three GWAS-detected genes as their upstream regulators.
We assessed CDT clustering in predefined functional categories using DAVID. We used seven sets of CDT genes: four for common cancers and three for most studied non-cancerous diseases.
To better assess if the enrichment of common downstream targets by the G1/S transition genes could have occurred due to random causes, we performed a permutation analysis. We randomly selected 83 genes from the Catalog of Published GWAS (Supplementary Material, Table S4 ). Eighty-three is the average number of associated genes among four common cancers we have analyzed. In total, 10 permutation tests were conducted. We have identified common downstream targets for the 10 sets of 83 genes and performed enrichment analysis. Supplementary Material, Table S4 shows the list of genes used in each permutation analysis.
We also conducted stratified enrichment analyses, by using CDTs identified by text mining only or PPIs only. For the stratified analyses CDTs were defined as genes with at least two upstream regulators that are GWAS-detected genes for a given disease. We used two upstream regulators in stratified analyses rather than three (which was done in the combined analysis) to keep the numbers of CDTs comparable.
We also conducted a gene set enrichment analysis stratified by the level of statistical significance of GWAS-detected disease associated SNPs. For the analysis, we categorized GWAS detected SNPs into those with genome-wide level of significance (GWLS) -those with P-value <5Â10 À 8 and sub-significant (SS) SNPs -those with 5 Â 10 À 8 < P < 10 À 5
. We identified CDTs for GWLS and SS genes separately for each disease and explored their clustering by biological function. Details on the stratified analysis are shown in Supplementary Material S1 (Supplementary Text S1, Supplementary Material, Tables S5  and S6 ).
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